Shogen Boku

26PUBLICATIONS
149CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Aug 07, 2026
cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

|Jul 28, 2026
Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel-Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan.

|May 18, 2026
Comprehensive Genomic and Transcriptomic Characterization of MTAP Loss across Advanced Solid Tumors.

|May 04, 2026
Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer.

|Mar 30, 2026
Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.

Yuqing Duan, Tadayoshi Hashimoto, Taro Shibuki

|Mar 25, 2026
Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells.

Nodoka Umezaki, Shogen Boku, Yoshiyuki Matsuo

Pageof 5

Frequent Collaborators

10 joint publications

Takayuki Yoshino

10 joint publications

Yoshiaki Nakamura

7 joint publications

Takao Fujisawa

7 joint publications

Hideaki Bando